Since our study showed that 31% of IBC patients had somatic and/or germline (pathogenic or likely pathogenic) mutations in genes involved in the homologous recombination repair (HRR) pathway (BRCA1, BRCA2, PALB2, RAD51C, BARD1, ATM), these patients would benefit from PARP inhibitors. The gene discussed is PALB2; the disease is inflammatory breast carcinoma.